Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection.
The last earnings update was 22 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sernova. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sernova's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sernova's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Sernova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sernova's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive, with over 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors. He serves at Clera Inc. He served as the Vice President of R&D Pharmacology and Drug Screening for Angiotech Pharmaceuticals, Inc., where he built a major scientific and information technology team. His major achievements at Angiotech included successful completion of Phase II European Clinical Trials, chairing the Joint Research Committee, in-licensing and out-licensing of technologies and management of key patents and patent applications. Dr. Toleikis's research training and experience art disease, cardiomyopathy, hypertension and aneurysms. Dr. Toleikis has been a Director of Sernova Corp. since June 29, 2009. He is the author of multiple issued patents and over 110 patent applications. Dr. Toleikis completed Post Doctoral work at the BC Cancer Agency and obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia He earned an M.Sc. at the University of Michigan and a B.A. at the University of Vermont.
Philip's compensation has increased whilst company is loss making.
Philip's remuneration is higher than average for companies of similar size in Germany.
Chief Financial Officer
Chief Science Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sernova board of directors is about average.
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.